Archive for 2011 Archive for 2010 Archive for 2009 Archive for 2008 Archive for 2007 Archive for 2006 Archive for 2005 Archive for 2004
Archive for 2003 Archive for 2001 Archive for 2000 Archive for 1999 Archive for 1998 1997 1995-1996  


2010 Archive
(listed in reverse chronological order)

February 16, 2011

Lilly  

Work  

Jennings  
How To Make Fistulas That Work (Parts 2 and 3)   
Michael P. Lilly, MD; Jack Work, MD; William Jennings, MD
(Fistula First Comprehensive Fistula Construction and Management Program for Surgeons. November, 2010.)  
Access free; register on HDCN to access.
Wrist Radiocephalic AVF
William Jennings, MD

Antebrachial AVFs
William Jennings, MD

Transposition AVFs
William Jennings, MD

Ectopic and Other Options
Michael P. Lilly, MD

Access Strategies: Discussion Panel
Drs. Michael P. Lilly, William Jennings, and Jack Work

Ultrasound Hands-on Demonstration
Drs. Michael P. Lilly, William Jennings, and Jack Work

Interventional/Surgical Revisions
Jack Work, MD

Secondary Fistulas: Converting Grafts Whenever Possible
Michael P. Lilly, MD

Challenging Patients: Extremes of Age & the Obese
William Jennings, MD

The Swollen Arm
Jack Work, MD

Steal Syndrome
Michael P. Lilly, MD

Questions & Answers/Panel Discussion
Drs. Michael P. Lilly, William Jennings, and Jack Work



Annual Dialysis Conference 2010
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2010)
(35 talks)
Improving Vascular Access Outcomes in Hemodialysis
Janet Holland MD; Vo D. Nguyen, MD; Lynda Ball, MSN, RN

Dialysis: Simple Solutions to Difficult Problems -- Part-2
John E. Moran, MB, BS; Brigitte Schiller, MD

Dialysis: Simple Solutions to Difficult Problems -- Part-1
John E. Moran, MB, BS; Brigitte Schiller, MD; John M. Burkart, MD; Bessie A. Young, MD; Robert M. Lindsay, MD

Survival in ESRD
Bessie Young, MD; John M. Burkart, MD; William L. Salzer, MD; Bryan R. Kestenbaum, MD

Membrane Health
Peter G. Blake, MB; Raymond T. Krediet, MD; Richard Amerling, MD

Futuristic Methods of Replacing Kidney Function
Andrew Davenport, MD; James R. Curtis, CHT; Eli A. Friedman, MD

Peritonitis and Technique Survival
William L. Salzer, MD; Beth Piraino, MD; Wai Kei Lo, MD; Jose A. Diaz-Buxo, MD; Martin Schreiber, MD

Joint Nutrition and Nursing Workshop: Wound Healing in Dialysis Patients
Mary Schira, PhD, RN, ACNP; Ann Cotton, MS, RD, LD; Brenda Patrick, MS, RN, APRN

Clinical HD Nursing Workshop II: Home Hemodialysis
Robert Pauly, MD; Lisa Koester, MSN, RN; Stacy Cigliana, RN; Sandip Mitra, MD

Nephrology Nursing II: Infections and Infection Control Practices
William Costerton, PhD; Priti Patel, MD


January 31, 2011

Lilly  

Work  
How To Make Fistulas That Work (Part 1)   
Michael P. Lilly, MD; Jack Work, MD;
(Fistula First Comprehensive Fistula Construction and Management Program for Surgeons. November, 2010.)  
Access free; register on HDCN to access.
Welcome and Announcements
Michael P. Lilly, MD

Why AVFs?
Jack Work, MD

Current Status/Areas for Improvement
Michael P. Lilly, MD

Role of Ultrasound
Michael P. Lilly, MD

Surgical Principles
Michael P. Lilly, MD

The Team Approach
Jack Work, MD



Annual Dialysis Conference 2010
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2010)
(15 talks)
Matters of the Heart: The Heart/Kidney Interaction
Madhukar Misra, MD; Kevin C. Dellsperger, MD, PhD; Charles Chazot, MD

DOPPS Update
Francesca Tentori, MD; Rajiv Saran, MD

Peritoneal Dialysis Technique Survival
Salim Mujais, MD; Joanne Bargman, MD; Peter G. Blake, MD

Controversies in Anemia of Chronic Kidney Disease
Kamyar Kalantar-Zadeh, MD; Ajay K. Singh, MD; Allen R. Nissenson, MD

The Hypertensive Patient on Hemodialysis: An Update
Mark J. Sarnak, MD; John T. Daugirdas, MD; Jula K. Inrig, MD; Charles Chazot, MD


January 4, 2011

V.Taaffe
J.Maltais
G.Rovegno
 

Maltais  

Concepcion  

Benner  
Where Do you Fit Into the Game? (Part 3)   
Panel (Vernon Taaffe, RPC; Jo-Ann Maltais PhD, George Roveno); Jo-Ann Maltais, PhD; Danilo Concepcion, CHT; Rich Benner CWSIII
(NANT Annual Meeting, March, 2010.)   Access free to all NANT members!
Panel of Pioneers: Perspective and Predictions;
Maltais: Ultrapure Dialysate: Present & Future Impact on Biomeds;
Concepcion: (Filling in for Jim Curtis) Home Dialysis: Impact On Biomeds;
Benner: Water for Patient Care Technicians (handout only; audiofile was not available).



Annual Dialysis Conference 2010
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2010)
(25 talks)
PERITONEAL DIALYSIS FUNDAMENTALS

PD Catheter Designs and Materials
Pranay Kathuria, MD

Experiences and Outcomes of PD Access Placement by Nephrologists
Fredric O. Finkelstein, MD

Experiences and Outcomes of PD Access Placement by Surgeons
W. Kirt Nichols, MD

Experience with the Extended Peritoneal Catheter
John H. Crabtree, MD

Update on Experiences with Embedded Peritoneal Catheters
Jack Moncrief, MD

Understanding How the PD Membrane Works
Isaac Teitelbaum, MD

Assessment of Peritoneal Membrane Function
Rajnish Mehrotra, MD

Writing PD Prescriptions: APD and CAPD - Case Studies
Martin Schreiber, MD

Adequacy in PD
John M. Burkart, MD

Management of Volume Overload in PD Patients
Mark D. Faber, MD

Update on Malnutrition Inflammation Atherosclerosis Syndrome and Outcomes in PD
Rajnish Mehrotra, MD

How Do Middle Molecules Impact on PD Outcomes?
Salim Mujais, MD

Membrane Types and Survival
Michael Flessner, MD, PhD

Encapsulating Peritoneal Sclerosis (EPS): Pathogenesis, Histopathology and Diagnosis
Michael Flessner, MD, PhD

Management of EPS Including Tamoxifen and Surgery
Steven S. Guest, MD

Nutritional Management of Patients with EPS: An Overview in All Phases
Mark D. Faber, MD

PD Catheter Exit-Site Care and Treatment Protocols for Exit-Site Infection
Beth Piraino, MD

Diagnosis and Treatment of Peritonitis in APD
Dana Negoi, MD

Catheter Removal in Peritonitis: Why, When and for How Long?
W. Kirt Nichols, MD

Prevention of Fungal and Bacterial Peritonitis
William L. Salzer, MD

Culture Negative Peritonitis and other Causes of Cloudy Dialysate
Michael V. Rocco, MD
Oral Hypoglycemic in Diabetics on PD
Katherine R. Tuttle, MD

PD in Patients with Chronic Liver Disease and Ascites
Steven S. Guest, MD

PD in Patients with Challenging Problems
Leslie P. Wong, MD

PD in Large, Anuric Patients
John E. Moran, MB


December 17, 2010

Arduino  

Payne  

Sweeney  
Where Do you Fit Into the Game? (Part 2)   
Matt Arduino, MS, DrPH; Glenda Payne, RN, MS, CNN; John Sweeney, BS, CHT;
(NANT Annual Meeting, March, 2010.)   Access free to all NANT members!
Arduino: Infection Control: What the Dialysis Techs Need to Know;
Payne: Medicare Conditions for Coverage: CMS Update on Surveys;
Sweeney: Dialysis Therapy in the 21st Century.


ANNA CE

(Article Free, $CE)
Clinical and Cost Effectiveness of Guidelines to Prevent Intravascular Catheter-Related Infections in Patients on Hemodialysis
(Vol 37/No. 6. Expires 12/20/2012)
Christine K. Bakke, DNP, APNP, CNN-NP, FNP-BC
1.3 hh

Frequency, Severity, and Distress of Dialysis-Related Symptoms Reported by Patients on Hemodialysis
(Vol 37/No. 6. Expires 12/20/2012)
Francess Victoria Nelson Danquah, PhD, RN, Lani Zimmerman, PhD, RN, FAAN, Pamela M. Diamond, PhD, Janet Meininger, PhD, RN, FAAN, and Nancy Bergstrom, PhD, RN, FAAN
1.3 hr

Peritoneal Dialysis Survival in Relation to Patient Body Size and Peritoneal Transport Characteristics
(Vol 37/No. 6. Expires 12/20/2012)
Barbara F. Prowant, MSN, RN, CNN, Harold Moore, MA, BS, BSE, Roberta Satalowich, RN, and Zbylut J. Twardowski, MD, PhD
1.2 hr



Annual Dialysis Conference 2010
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2010)
(10 talks)
Mineral Bone Disease in Chronic Kidney Disease (CKD): Where are We on the Learning Curve?
Ian de Boer, MD; Bryan R. Kestenbaum, MD; and Harbaksh S. Sangha, MD

Joint Nutrition and Nursing Clinical Topics: Calcium and Phosphorus Management
Linda McCann, RD, CSR, LD and Kamyar Kalantar-Zadeh, MD, PhD

Fundamentals, Day I
Jean L. Holley, MD; Dimitrios Oreopoulos, MD, PhD; Leslie P. Wong, MD; and Fredric O. Finkelstein, MD


November 30, 2010

Powe  

Lok  
Infectious Risk in Renal Replacement Therapy   
Neil R. Powe, MD and Charmaine E. Lok, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Powe: How might statins protect against infection? What is the evidence of a protective effect in subjects with normal renal function? What are potential mechanistic explanations for a statin-protective action against infection? What to trials of bacteremia and sepsis show? What was found in the CHOICE study regarding this issue? What is the rationale for intravenous iron therapy being a risk factor for infection? Does IV iron increase the risk of infection in human studies? What do animal studies show? Lok: What are primary and secondary preventive approaches for bacteremia prevention in dialysis patients? How does infection impact on outcome in ESRD? How great is the impact of having an AV fistula for hemodialysis patients in terms of reducting infectious risk? What is the role for prophylaxis to prevent exit-site and/or nasal colonization by pathogenic bacteria? What are the advantages vs. risks of antibiotic lock solutions? What methods can we use to track antibiotic resistance?

Where Do you Fit Into the Game?
(NANT Annual Meeting, March, 2010.)   Access free to all NANT members!

Change is Coming – Are You Ready?
Tony Messana

Climbing Your Career Ladder - Part-1
P. Varughese, CHT

Climbing Your Career Ladder - Part-2
J. Curtis, CCHT, CHT

Role of IT in Dialysis and How it has Evolved
G. Rovegno


 

Annual Dialysis Conference 2010
now in MP3
AUDIOFILE LIST (Annual Dialysis Conference 2010)
(15 talks)
Clinical Issues and Concerns, Part I
Jack Moncrief, MD, John E. Moran, MB, BS , Steven S. Guest, MD and Dimitrios G. Oreopoulos, MD, PhD

Clinical Issues and Concerns, Part II
Kevin C. Dellsperger, MD, PhD, Katherine R. Tuttle, MD, James Sloand, MD, and Kunal Chaudhary, MD

Practical Management of the Patient with Acute Kidney Injury (AKI)
Sergio Zanotti, MD; Andrew Davenport, MD; Rajiv Dhand, MD; and Thomas A. Golper, MD

Daily Hemodialysis: An Update on On-Going Registries and Clinical Trials
Robert M. Lindsay, MD; Nathan W. Levin, MD; and Michael V. Rocco, MD


October 31, 2010

Voorhees  

Madore  
Multiple Myeloma: Novel Treatments and Role of Plasmapheresis   
Peter M. Voorhees, MD and François Madoré, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Voorhees: What are the factors that suggest multiple myeloma may adversely impact renal function? What are the novel treatment strategies in these disease, specifically, immunomodulatory drugs such as lenalidomide, proteasome inhibitors such as bortezomib, and autologous stem cell transplantation? What is the role of dexamethasone? What is the pharmacology of the newer agents in patients with reduced renal clearance? Madoré: What is the rationale for plasmapheresis in treatment of multiple myeloma? What have the randomized trials shown? What do recent, non-randomized studies add? What trials are ongoing? What conclusions can we make at this stage and what are current recommendations for therapy?


ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

The Buttonhole Technique: Strategies to Reduce Infections
(Vol 37/No. 5. Expires 10/20/2012)
Lynda K. Ball, MSN, RN, CNN
1.0 hr

Hemodialysis Catheter Care: Current Recommendations for Nursing Practice in North America
(Vol 37/No. 5. Expires 10/20/2012)
Lesley C. Dinwiddie, MSN, RN, FNP, CNN, and Cynthia Bhola, MN, BN, RN, CNephC
1.5 hr



October 17, 2010

Van Biesen  

Mujais  

Lindholm  
Is Peritoneal Dialysis Membrane Failure Inevitable with Long-term Use?   
Wim Van Biesen, MD, PhD, Salim K. Mujais, MD, and Bengt Lindholm, MD, PhD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Van Biesen: How do we perform an acute point-in-time evaluation of peritoneal transport to define the optimal treatment regimen for a peritoneal dialysis patient? What is the role of chronic longitudinal follow-up to help in prognostication? How does peritoneal transport physiology of the membrane change over time? Mujais: What is the pathophysiology of encapsulating peritoneal sclerosis? What are the suspected operative mediators? How does one diagnose this condition? Is computed tomography useful? What are problems associated with interpretation of peritoneal biopsy in this condition? Lindholm: How do we manage encapsulating peritoneal sclerosis? What is the role of tamoxifen? Are the newer peritoneal dialysis solutions protective? What are the results of surgery? What is the long-term prognosis?


September 30, 2010

Hildebrandt  

Chevalier  
Renal Diseases of Children in Adults   
Friedhelm Hildebrandt, MD and Robert L. Chevalier, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Hildebrandt: How can nephronophthisis present in adolescents and adults? What are the genetic variants and how do they differ in terms of when disease presents? What genetic diseases involve mutations in proteins involved in ciliary function? How are cilia involved in organogenesis? What organs other than the kidneys are involved and why? What ciliopathies manifest in children and adults? Chevalier: What are the different forms of congenital urinary obstruction and what is the consequence of each? After relief of obstruction, why can disease recur in adolescence and present with ESRD? What is the role of ACE inhibitors? When can they be harmful? When should one intervene and when is watchful waiting appropriate?


ASDIN  
ASDIN National Meeting. February, 2010. Parts 11-12.
Free to ASDIN members.
  
Flash slide/audio; MP3 audio
PART XII
NEXT STEPS IN RESEARCH
National Database for Vascular Access Outcomes
Timothy A. Pflederer, MD

Steps Toward Device Innovation
Bart Dolmatch, MD

Grant Writing and Vascular Access Research: in Academics and the Community Building
Ivan Maya, MD

PART XI
THE POLITICS OF HEALTHCARE AND INTERVENTIONAL NEPHROLOGY
Academic Partnerships
Bryan N. Becker, MD

Interventional Nephrology as a Subspecialty of the ABIM
Stuart L. Linas, MD

Lobbying Efforts and Coalition Building
Edward R Jones, MD


September 17, 2010

Palmer  

Fervenza  
Nephrology Quiz and Questionnaire: Fluids and Electrolytes (Palmer) and Glomerular Disorders (Fervenza)   
Biff F. Palmer, MD, and Frenando C. Fervenza, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Palmer: Case 1: Woman treated for pyelonephritis returns weak, with downbeat nystagmus, and with hypokalemia alkalosis. Is it due to the drugs she was treated with, Gitelman's syndrome, or surreptitious diuretics abuse? What's causing the nystagmus? Case 2: Fashion model with hypokalemia alkalosis and an ammonium urate stone. Is it diuretic abuse? Laxative abuse? Vomiting? Bartter syndrome? or Sjogren syndrome? Can you explain all of the electrolyte abnormalities? Fervenza: Case 1: Woman with MPGN presents with worsening creatinine and 17 g/day proteinuria. On repeat biopsy, what is found? Pauci-immune necrotizing and crescentic GN? Cryoglobulinemic GN? MPGN with monoclonal gammopathy? Diffuse proliferative lupus GN? Case 2: A 60-year old male with amyloidosis. Serum immunofixation is negative. Congo red stain is positive. SAP positive, SAA negative. What should the next step be in terms of evaluation or treatment?


ASDIN  
ASDIN National Meeting. February, 2010. Parts 9-10.
Free to ASDIN members.
  
Flash slide/audio; MP3 audio
PART X
Epidemiology of Vascular Access
Recent Advances in our Understanding of AVF Maturation
Jeffrey Hoggard, MD

Fistula First Impact on AVF, AVG, Catheters: an Update
Anil Agarwal, MD

Vascular Access and Mortality
Haimanot Wasse, MD

PART IX
Expanding the Scope of Interventional Nephrology Practice
From Training to Practice: What are the Practical Steps and Pitfalls
Jan Bijan Tawakol, MD

Arterial Intervention: Angioplasty and Stent Placement
Arif Asif, MD

Renal Artery Intervention
Alexander Yevzlin, MD


August 26, 2010

Flynn  

Kavey  
The Approaching Tidal Wave of Hypertension and Its Sequelae in the Young   
Joseph T. Flynn, MD and Rae-Ellen W. Kavey, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Flynn: How do we define hypertension in children? What is the prevalence? What are the risk factors for an elevated blood pressure? What is the relative importance of HTN as a cause of ESRD in kids? What is the CKiD study? What are blood pressures in this study? How does elevated blood pressure related to progression? What are the findings regarding blood pressure and CKD in the European ESCAPE study? Kavey: How do we define obesity in adolescence? What are the trends for increasing obesity in children? How does obesity relate to hypertension? What are the methodologic difficulties in measuring blood pressure in children? What are the guidelines regarding measurement, classification, and management of blood pressure in kids? What do guidelines recommend re cardiovascular risk reduction?


ASDIN  
ASDIN National Meeting. February, 2010. Parts 6-8.
Free to ASDIN members.
  
Flash slide/audio; MP3 audio
PART VIII
New Directions in Autogenous Fistula Creation and Maintenance Overview of Current Trends: High Pressure Balloons, Extended Time Angioplasties, and Advanced Techniques
Aris Q. Urbanes, MD

What is the Ideal Ultrasound Access Planning Technique?
Michelle Robbin, MD

The Future of Nephrology-placed AVF Training
Jeffrey Packer, DO

PART VII
New Directions in Central Venous Catheters

The Effect of Lock Solutions on Infection and Patency
Stephen R. Ash, MD

The Effect of Catheter Coatings on Infection and Patency
Amy Dwyer, MD

How Does One Implement New Catheter Technology in the Community?
Sumit Kumar, MD

PART VI
Annual State of the Art Lecture
Where We began, Where We Are Now, and Where We Are Headed
Gerald A. Beathard, MD


ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Intra-Operative Hemodialysis During Liver Transplantation: An Expanded Role of the Nephrology Nurse
(Vol 37/No. 4. Expires 8/20/2012)
Angela Henson, MN, RN,and Sally Carpenter, BN, RN
1.0 hr

Negotiating Living with an Arteriovenous Fistula for Hemodialysis
(Vol 37/No. 4. Expires 8/20/2012)
Cleo J. Richard, PhD, MSN, RN, CNS,and Joan Engebretson, DrPH, AHN-BC, RN
1.3 hr



August 3, 2010

Budoff  

Ketteler  
Vascular Calcification   
Mathew Jay Budoff, MD and Markus Ketteler, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Budoff: How does coronary calcification associate with mortality in the general population? In the CKD population? To what extent do intimal vs. medial calcification have different prognoses? How does coronary calcification compare with other risk factors for cardiovascular disease? Is coronary calcification a valid marker for CV risk in dialysis patients? Ketteler: What are the different methods available for imaging vascular calcification in dialysis patients? What do the 2009 KDIGO CKD-MBD guidelines recommend about this? What impact does this have in terms of choice of phosphate binders? What do the KDIGO guidelines recommend in terms of optimal calcium and phosphate levels in CKD? what are the implications for limiting calcium exposure in CKD?


ASDIN  
ASDIN National Meeting. February, 2010. Parts 3-5.
Free to ASDIN members.
  
Flash slide/audio; MP3 audio
PART V
AVF Creation in the Elderly Patient: Should We Consider “Graft First?”
Michael Allon, MD

Last Resort Strategies in the “End-stage” Access Patient
John R. Ross, MD

PART IV
Stenting of AV Access
Arif Asif, MD

Covered Stent at the Venous Anastomosis as the Primary Intervention
Bart Dolmatch, MD

Secondary AVF Creation: Be Careful What You Stent
Rizwan A. Qazi, MD

PART III
Recent Contributions to our Understanding of Vascular Biology
Prabir Roy-Chaudhury, MD

Pharmacologic Intervention to Enhance Maturation and Prevent Dysfunction of AV Access
Prabir Roy-Chaudhury, MD

New Developments in Synthetic and Biological AV Grafts
Bharat Sachdeva, MD


July 20, 2010

ASDIN  
ASDIN National Meeting. February, 2010. Parts 1-2.
Free to ASDIN members.
  
Flash slide/audio; MP3 audio
PART I. Billing, Coding, and Policy
Ethics and Communication in Vascular Access Care
Jamie Ross, MD

Legal Issues and Interventional Practice
John F. McGreevey

Recent Changes in Coding Policy
Gerald A. Beathard, MD

PART II. New Directions in Peritoneal Dialysis and Ultrasound
Creating a PD Curriculum
Steven Wu, MD

PD as a Central Venous Catheter Avoidance Strategy
Kenneth Abreo, MD

Ultrasound and HD Access
Vandana Dua Niyyar, MD


June 30, 2010

Sterns  

Adrogue  

Verbalis  
Management of Hyponatremia   
Richard H. Sterns, MD; Horacio J. Adrogue, MD; and Joseph G. Verbalis, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Sterns: Three cases are presented. The first is a young woman found comatose after taking multiple tablets of ecstasy and large quantities of water while dancing at a party. The second is a middle-aged woman beer drinker who develops lethargy and weakness 2 weeks after starting treatment with a thiazide and SSRI. The third is a woman with depression treated with SSRI who is found to have Na of 124 mmol/L but who is asymptomatic. Why, why, and why? Adrogue: How do we approach dilutional hyponatremia? How is its pathogenesis determined? How does pathogenesis guide therapy? What equations or formulas can we use to help us diagnose and treat? How do we monitor patients during treatment to avoid overcorrection? Three illustrative cases are presented. Verbalis: What is a good treatment algorithm for euvolemic hyponatremia? What is its pathogenesis? How can we induce aquaresis? What are symptoms associated with hyponatremia? What is the pathogenesis of neurologic damage? How does hyponatremia affect gait stability? How does hyponatremia relate to osteoporosis? How do we practically dose and use the vaptans? Who are candidates for this therapy?


June 17, 2010

Mottl  

Tuttle  
Diabetic Nephropathy   
Amy Katherine Mottl, MD and Katherine R. Tuttle, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Mottl: What is the variability in the clinical course of diabetic nephropathy? What is the predictive power of hyperfiltration? What is the rate of spontaneous regression of albuminuria? To what extent does the nephropathy regress after pancreatic transplant? What is typical and atypical renal histology in type 2 DM and what are the implications for prognosis? What are the histologic predictors of GFR decline? What characterizes nonproteinuric diabetic nephropathy? Tuttle: What are the novel treatments in development? Sulodexide? Ruboxistaurin? Anti-AGE treatments such as pyridoxamine? Anti-fibrotic treatments such as perfenidone, Anti-CTGF or anti-TGF antibodies? Rhubarb extract? Anti-oxidants? Endothelin antagonists? Vitamin D?


ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Compliance, Normality, and the Patient on Peritoneal Dialysis
(Vol 37/No. 3. Expires 6/20/2012)
Alexandra McCarthy, PhD, RN, Ramon Shaban, PhDc, RN, Jennifer Boys, MHSc, RN, and Sarah Winch, PhD, RN
1.0 hr

Organ Donation Experiences of Family Members
(Vol 37/No. 3. Expires 6/20/2012)
April Manuel, MN, BN, Shirley Solberg, MN, BN, BA, PhD, and Sandra MacDonald, PhD, RN
1.3 hr

Relationship between Illness Perceptions, Treatment Adherence, and Clinical Outcomes in Patients on Maintenance Hemodialysis
(Vol 37/No. 3. Expires 6/20/2012)
Kandace Youngmee Kim, PhD, RN, FNP-C, and Lorraine S. Evangelista, PhD, RN
1.5 hr

Understanding the Negative Effects of Depressive Symptoms in Patients with ESRD Receiving Hemodialysis
(Vol 37/No. 3. Expires 6/20/2012)
Amani A. Khalil, PhD, RN, Terry A. Lennie, PhD, RN, and Susan K. Frazier, PhD, RN
1.3 hr

Legal Nurse Consultant: A Role for Nephrology Nurses
(Vol 37/No. 3. Expires 6/20/2012)
Rowena Elliott, PhD, RN, CNN, BC, LNC, and Kristin Larson, RN, ANP, GNP, CNN
1.0 hr

Quality of Life Measures for Patients on Hemodialysis: A Review of Psychometric Properties
(Vol 37/No. 3. Expires 6/20/2012)
Francess Victoria Nelson Danquah, PhD, RN, Joan Wasserman, DrPH, MBA, RN, Janet Meininger, PhD, RN, FAAN, and Nancy Bergstrom, PhD, RN, FAAN
1.4 hr



ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)  
(24 talks)
Vascular Calcification in CKD: Roles of Mineral Metabolism Disorder and Cross-talk with Bone
M. Rodriguez, D.A. Towler, R.C. Shroff, B.R. Kestenbaum

Therapies and Therapeutic Targets on the Horizon for Hypertension
H.M. Siragy, M.C. Thomas, D.J. Webb, M.J. Brown

The Renal Basis of Hypertension and Edema
T.R. Kleyman, O. Staub, A.A. McDonough, J. Loffing

The History and Challenges Involving Nephrology and the FDA
E.J. Lewis, A.M. Thompson, R.M. Califf, J. Himmelfarb

Signaling at the Slit and Beyond: Podocytes and Fruit Flies
L.B. Holzman, R.L. Cagan, N. Jones, B. Denholm

Nephron Formation from Beginning to End
S.S. Potter, A.P. McMahon, L.G. Cantley, L.T. Patterson



May 30, 2010

RRI
Advances in CKD 2010 (Parts 3 and 4)  

Immune mechanisms involved in CV complications of CKD
Roberto Pecoits Filho, MD

Blood pressure in HD: when, where and what to measure? What are the targets for control?
Rajiv Agarwal, MD

Infectious diseases in CKD, HD and transplantation
Warren Kupin, MD

Management of depression in CKD patients
Fredric O. Finkelstein, MD

Ethnicity and renal failure - an international question
John Feehally, DM, FRCP

How is having Chronic Kidney Disease like taking the Boards?
Klemens Meyer, MD

The gastro-intestinal system: a void in understanding of uremic toxicity?
Peter Kotanko, MD

Phosphate elimination in modalities of hemodialysis and peritoneal dialysis
Martin Kuhlmann, MD

Glucose in PD: glucose reduced diet, glucose toxicity
John Burkart, MD

Does PD modality choice make a difference to peritonitis occurrence?
Beth Piraino, MD

Keynote Address : Scaling in human biology relevance for health and disease
John R. Speakman, PhD

EPC and EPC vesicles: what is their significance for CKD patients?
Mark S. Segal, MD

Potassium control in CKD with specific emphasis on ACE/ARB/mineralocorticoid receptor blocker
Sheldon Hirsch, MD

Non-erythropoietic effects of ESAs
Michael Brines, MD, PhD

Special considerations for use of anti-hypertensive agents in dialysis patients
Heleen Josep Redon, MD, PhD, FAHA

Debate: Calcium balance in dialysis is best managed by changing Dialysate calcium - YES
Frank Gotch, MD

Debate: Calcium balance in dialysis is best managed by changing Dialysate calcium - NO
Sharon M. Moe, MD

Aldosterone in uremia – beyond blood pressure
Eberhard Ritz, MD




ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)  
(23 talks)
Nephrolithiasis
Y. Lotan, R.V. Thakker, M.E. DeBroe, D.S. Goldfarb

Kidney-Brain: Emerging Parallels in Cell Biology
T.J. Jentsch, D.B. Mount, T.E. Willnow, G.A. Rouleau

Inflammation and Immune Tolerance
A. Chandraker, M.J. Ansarai, M.L. Alegra

Defense Mechanisms Against Acute Kidney Injury
J.K. Chen, K. Bomsztyk, C.E. Edelstein, G. Camussi

Appealing to the Base: New Approaches to Diagnosis and Treatment of Acidosis in the ICU
W.F. Boron, J.A. Kellum, A. Rastegar, R.L. Mehta

An Expanding Role for HIF and VHL in the Kidney
R.S. Johnson, P.H. Maxwell, V.H. Haase, K.U. Eckhardt



May 10, 2010

RRI
Advances in CKD 2010 (Part 2)  

Wearable artificial kidney - from holy grail to reality
Victor Gura, MD

Bioartificial kidney - ready for prime time?
H. David Humes, MD

Citrate anticoagulation for RRT in acute kidney injury
Heleen M. Oudemans-van Straaten, MD

Citrate anticoagulation in chronic hemodialysis
Stephan Thijssen, MD

Citrate anticoagulation technical barriers and potential solutions
Balazs Szamosfalvi, MD

Using affinity plasmapheresis to markedly improve antiviral drug treatments for hepatitis C: A new approach
Richard H. Tullis, PhD

Evidence based nephrology - what has been achieved up to now?
Jonathan C. Craig, MD

Novel insights into the pathobiology of vascular access - Do they translate into improved care?
Charles J. Diskin, MD

Debate: Are there optimal fistula and catheter rates and should these be mandandated?
YES - Arif Asif, MD; NO - Richard Amerling, MD



RPA
RPA Annual Meeting 2010 (Sessions I - V)  
(free access to RPA members)

General Session I. Kidney Care: State of the Art and Charting the Challenges for the Future
Welcome
Franklin Maddux, MD

RPA Year in Review
Edward Jones, MD

RPA Advocacy Agenda
Robert Blaser

The State of Renal Care in the U.S. – An Update
Tom Parker, MD

Investing in Your Practice Growth: Business Planning
Gerald Stephanz, MD

General Session II: Changing Delivery Models for Renal Care
Louis Diamond Lecture: Quality Measurement and Reporting: Opportunities and Perils
Greg Pawlson, MD

ARRA, Incentives and Policy in HIT: Impact on Nephrologists
Janet Corrigan, PhD

General Session III: Life in the Time of Clinical Practice: Balancing a Nephrology Career and Family Life
RPA Young Physicians Survey Results
Adam Weinstein, MD

Succession Planning in the Nephrology Practice
Moderator: Robert Pristave; Panel: Candace Walworth, MD, Charles Cooperberg, MD, and Joseph Kuhn MD

General Session IV: The Next Level of Clinical Care for CKD Patients
Improving CKD Patient Outcomes: Results of RPA’s Toolkit Fieldtest
Moderator: William Haley, MD; Panel: Robert Kossmann, MD; Monica Alvarez; Richard Goldman, MD; Elizabeth Evans

Comorbid Disease Management in Renal Disease: The X Factor
Allen Nissenson, MD

What Does Optimal Vascular Access Management Look Like?
Gerald Beathard, MD

General Session V: What Does the Federal Government Have in Store for Nephrology Practice?
Changing the Practice Paradigm through Accountable Care Models
Franklin Maddux, MD

John Dickmeyer Lecture: Health Care Reform and Your Nephrology Practice
Barry Straube, MD

The Impact of Bundling on the Nephrology Practice
Jeffrey Hymes, MD

ESA in Anemic Related Kidney Disease
Alan S Kliger MD



ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)  
(36 talks)
A Bench to Bedside View of Uremic Toxins
R.C. Vanholder, P. Brunet, T.W. Meyer, Z. Massy

Updates on Clinical Trials: CRIC, CKiD, AASK Cohort, and FSGS Trial Finding
B.A. Warady, E.R. Miller, F.J. Kaskel

Thrombotic Microangiopathies: The Complement-Clot Connection
G. Remuzzi, D.G. Motto, S.A. Karumanchi, E.M. Conway

Thick Ascending Limb Function and Dysfunction: The Steven C. Hebert Memorial Symposium
G. Gamba, J.B. Schnermann, P.A. Ortiz, T. Wang

The Epigenetic Epidemic: Understanding the Grammar of Genetic Language
A. Petronis, G.R. Dressler, J.A. Kreidberg, A. El-Osta

Reprogramming and Induced Pluripotency: Does this Apply to the Kidney?
M.N. Rivera, S.Ding

Renal Anemia and ESA
M.J. Percy, J. Chen, J. Malyszko

Molecular Mechanisms of Nephrotic Syndrome: Novel Insights
M.R. Daha, R.C. Wiggins, D. Dil Sahali, D.J. Salant

Molecular and Cellular Mechanisms of Phosphate Control
M.S. Razzaque, R.J. Unwin, E.J. Weinman, D. Prie

Macrophages and Mast Cells in Renal Injury and Health
M. Karin, S.R. Holdsworth, M. Hewison, D.C. Harris



April 18, 2010

Parving  

Mann  
Debates in Renal Disease 2: Combination of ACEI and ARB is More Efficacious than Monotherapy   
Hans Henrik Parving, MD, and Johannes F.E. Mann, MD (Moderator: Ricardo Correa-Rotter, MD)
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Parving: Yes, dual therapy is better! High level of tissue RAAS in diabetes and CKD; Good results in CHF (CHARM-added and Val-HeFT); albuminuria is a good surrogate marker for CVD and renal events, especially changes in albuminuria; good results in AVOID; ONTARGET flawed by low incidence of proteinuria, assessment of creatinine, use of ARB of questionable efficacy (telmisartan); safety issues (hyperkalemia, drop in GFR) must be kept in mind; may be best when proteinuria is marked. Mann: COOPERATE study retracted; ONTARGET very large study; dual therapy for heart failure comes at a cost; albuminuria a flawed surrogate endpoint; trend for renal endpoints in ONTARGET was for worse results with dual therapy, including worsening renal function.


RRI
Advances in CKD 2010 (Part 1)

What a nephrologist should understand about a dialysis machine?
Richard A. Ward, PhD

How changes in dialysate water quality, sodium, calcium, potassium and bicarbonate affect clinical outcomes?
Nicholas A. Hoenich, PhD

What is expected of a medical director in the new CMS Conditions of Coverage?
Peter B. DeOreo, MD

How bundling will affect hemodialysis?
Ronald J. Kuerbitz, Esq.

How should we prescribe dialysis?
Robert A. Gutman, MD

Keynote Address : Guidelines for the management of kidney transplant recipients
Bertram L. Kasiske, MD

Intradialytic hypotension - how to deal with a frequent problem
Frank van der Sande, MD, PhD

Gelsolin: biology and clinical correlates
Po-Shun Lee, MD

How to successfully achieve salt restriction in HD patients; what are the outcomes?
Ercan Ok, MD

The cardio-renal substrate leading to sudden death in dialysis patients
Charles A. Herzog, MD

Myocardial stunning in CKD - a new aspect of cardiovascular disease
Chris W. McIntyre, MD



ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Identification of Modifiable CKD Risk Factors by Gender in an African-American Metabolic Syndrome Cohort
(Vol 37/No. 2. Expires 4/20/2012)
Loretta Jackson Brown, MSN, RN, CNN, Patricia C. Clark, PhD, RN, FAAN, Sandra B. Dunbar, DSN, RN, FAAN, Karen A. Armstrong, MA, RN, OCN, and Zhao Liping, MS, DDS
1.4 hr

The Emotional Impact of Malpractice
(Vol 37/No. 2. Expires 4/20/2012)
Kristin Larson, RN, ANP, GNP, CNN, and Rowena Elliott, PhD, RN, CNN, BC, LNC
1.2 hr

Perceived Informational Needs, Problems, or Concerns among Patients with Stage 4 CKD
(Vol 37/No. 2. Expires 4/20/2012)
Andrea L. Lewis, MSN, RN, ACNS-BC, CNN, Kellee A. Stabler, MSN, RN, ACNS-BC, CNN, and Janet L. Welch, DNS, RN, CNS
1.4 hr

A New Nursing Model for the Care of Patients with CKD: The UNC Kidney Center Nephrology Nursing Initiative
(Vol 37/No. 2. Expires 4/20/2012)
Clara D. Neyhart, BSN, RN, CNN, Lynn McCoy, RN, CNN, Beverly Rodegast, RN, Constance A. Gilet, MSN, ANP, Cynthia Roberts, RN, CNN, and Kelley Downes, BSN, RN
1.5 hr

Perceptions of a Multiple Kidney Transplant Recipient: Understanding a Fragile Life
(Vol 37/No. 2. Expires 4/20/2012)
Karen Wilson Scott, PhD, and Guy M. Hollingsworth, PhD
1.4 hr



ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)
(29 talks)
Immunosuppression Update
D.C. Brennan, D.J. Norman, F.G. Vincenti, R.E. Morris

Biomarkers in Kidney Disease
J.B. Klein, R.E. Gerszten, P. Rossing, S.G. Coca

Aging: Is the End Inevitable?
J.A. Baur, T.K. Blackwell, A. Aviv, S.K. Kim

Novel Imaging Techniques and Biology
D. Piston, R. Weigert, N.R.J. Gascoigne, M.A.A. Arnaout

A Fresh Look at Atherogenesis
S. Fazio, T.H. Le, P.W. Shaul, V. Krane

Plenary Session IV: Belding H. Scribner Award Presentation (Cimino); State-of-the-Art Lecture: Signal Transduction Mechanisms in the Kidney (Pawson)
J.E. Cimino, T.J. Pawson

Plenary Session III: Homer Smith Award and Address: Minerals in Motion: From Renal Transporters to New Concepts (Bindels); State-of-the-Art Lecture: Genetic Insights into the Innate Immune System (Beutler)
R.J. Bindels, B. Beutler

Plenary Session II: Young Investigator Award Presentation (Kretzler); Narins Award Presentation (Rose); State-of-the-Art Lecture: Towards New Understanding and Therapies of Glomerular Disease (Tryggvason)
M. Kretzler, B.D. Rose, K. Tryggvason

Plenary Session: President's Address (Coffman); John P. Peters Award Presentation (Mitch); tate-of-the-Art Lecture: Breeding and Building Molecules for Whole-Animal and Clinical Imaging (Tsien)
T.M. Coffman, W.E. Mitch, R.Y. Tsien



March 25, 2010

Appel  

Clark  
The Thrombotic Microangiopathies   
Gerald Appel, MD and William F. Clark, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Appel: Treatment of TTP and the prevention of relapses. Do we wait for an ADAMTS13 level to treat? What initial therapy is best? Plasma exchange vs. plasma infusion? Should glucocorticoids be used? When should rituximab be used? Cyclosporine? Vincristine? IVIG? What is the chance of relapse of TTP, and what should the therapy be then? Clark: What is the incidence of secondary vs. primary thrombotic microangiopathy? How does the pathogenesis differ? What are the main secondary causes? What are ADAMTS13 levels in secondary vs. primary disease? To what extent should initial treatment differ? How does one go about ruling out a secondary cause?


ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)
(34 talks)
Late-breaking clinical trials
A.G. Bostom, D. De Zeeuw, M. Pfeffer, H.G. Haller, A. Cass

Kidney Disease Improving Global Outcomes (KDIGO) Update
K-U. Eckardt, B.L. Kasiske, N.W. Levin, A.S. Levey

ESRD: State-of-the-Art and Charting the Challenges for the Future
A.J. Collins, W.M. Bennett, R.J. Glassock, T.F. Parker

ClinicoPathologic Conference (CPC)
S.J. Shankland, A.J. Howie

Modifiable Hemodialysis Practices: Latest Trends and Outcomes from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
B.M. Robinson, D.C. Mendelssohn, B.J. Canaud, R.J. Fluck, R.C. Vanholder

ASN Public Policy Board Symposium- Health Care Delivery: Repairing a Broken System
R.D. Cebul, A.C. Enthoven, A. Levin

USRDS
A.J. Collins, J.J. Snyder, B.L. Kasiske, A. Ishani, K.L. Johansen

Public Policy Forum: Conflicts of Interest in Medicine, Christopher R. Blagg Endowed Lectureship
A.S. Detsky, B. Lo, R.M. Califf



March 2, 2010

Radhakrishnan  

Cattran  

Kopp  
The Changing Face of FSGS/MCD   
Jai Radhakrishnan, MD; Daniel C. Cattran, MD; and Jeffrey B. Kopp, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Radhakrishnan: How should we treat minimal change disease on initial presentation? How should we treat patients who are frequent relapsers? Those who are refractory to therapy? Should treatment be changed for the C1Q and IgM variants? How is adult MCD different from that in children? Cattran: What is the value of achieving partial remission in FSGS? Should initial treatment still be steroids, especially in older patients, or obese patients? If not, what might be alternatives for initial treatment? What do the other options include? Is cyclosporin the best? What about tacrolimus? MMF? Rituximab? Pirfenidone? Kopp: In treating FSGS, is pulse oral dexamethasone and alternative to daily steroids? What are the results with rituximab or adalimumab in treating FSGS? Is there a role for pirfenidone, for rosiglitazone, and for retinoids such as isotretinoin? What do the preliminary results show?


ANNA CE

(Article Free, $CE)
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Quality of Life in Patients Undergoing Hemodialysis and Renal Transplantation A Meta-Analytic Review
(Vol 37/No. 1. Expires 2/20/2012)
Kandace Landreneau, PhD, RN, CCTC, Kathryn Lee, PhD, RN, FAAN, and Michael D. Landreneau, MD
1.3 hr

The Dual Vitamin D Pathways: Considerations for Adequate Supplementation
(Vol 37/No. 1. Expires 2/20/2012)
Susan C. Cronin, MS, RN
1.4 hr

Seeking Optimal Renal Replacement Therapy Delivery in Intensive Care Units
(Vol 37/No. 1. Expires 2/20/2012)
Marinka Kocjan, MN, RN, CNCC(C), and Fabrice P. Brunet, MD, FRCPC
1.3 hr



ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)
(23 talks)
Sex and the Kidney
P. August, S.B. Ahmed, S.A. Karumanchi, and J.A. Miller

Multiple Myeloma
G.A. Herrera, P.M. Voorhees, F. Madore, J.A. Katzmann

Management of Hyponatremia
R.H. Stenrs, H.J. Adrogue, J.G. Verbalis

The Approaching Tidal Wave of Hypertension and Its Sequelae in the Young
B. Falkner, S.R. Daniels, J.T. Flynn, R-E. W. Kavey

The Kidney in End Stage Liver Disease
R.W. Schrier, T.A. Gonwa, A. Davenport, and P-Y. Fan

Renal Diseases of Children in Adults
M.E. Ferris, F. Hildebrandt, R.L. Chevalier, and S. Goldstein



February 18, 2010

Bloom  

Brown  
Hepatitis C and Renal Disease   
Roy D. Bloom, MD and Robert S. Brown, Jr, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Bloom: What are the characteristics of transplant candidates infected with hepatitis C? What is the impact of HCV infection on patient and graft survival? On hepatic complications? On new onset diabetes (NODAT)? Glomerulonephritis? Infection? Does liver disease progress after transplantation? What is the role of pretransplant interferon? What are useful patient management algorithms? Brown: What are the goals of antiviral therapy of HCV? How durable is a sustained virologic response? How is this affected by duration of interferon therapy and dosage of ribavirin? How is treatment different in genotype 1 vs. 2 and 3 disease? What should be the virologic monitoring strategy? What are issues of using interferon and especially, ribavirin, when renal function is decreased? What are the complications? What is the data with emerging therapies for HCV, including polymerase and proteinase inhibitors? What is the role of triple therapy? Re-treatment?


ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)
(52 talks)
Is Peritoneal Dialysis Membrane Failure Inevitable with Long-term Use?
A. Breborowicz, W Van Biesen, S. K. Mujais, and B. Lindholm

Important Clinical Trials in Transplantation
H. Ekberg, F. G. Vincenti, J. D. Schold, and S. M. Flechner

Diabetic Nephropathy
A. K. Mottl, M. E. Williams, J. Lewis, and K. R. Tuttle

Update in Acute Kidney Injury (AKI)
S. S. Waikar, P. W. Eggers, S. Goldstein, and P. M. Palevsky

The Importance of Proteinuria as a Surrogate for Outcome in CKD
T. H. Hostetter, A. M. Thompson, G. Remuzzi, D. De Zeeuw and T. H. Greene

Quotidian (Daily) Dialysis
A. S. Kliger, C. T. Chan, M. L. Unruh, and B. J. Manns

Nephrology Quiz & Questionnaire
J. M. Bargman, B. F. Palmer, M. D. Samaniego-Picota, and F. C. Fervenza

Glomerular Injury in Progressive Renal Disease
S. G. Adler, J. C. Jennette, E. Ritz, and J. F. Bertram

Debates in Renal Disease 2: Combination of ACEI and ARB is More Efficacious than Monotherapy
H. Paraving, and J. F. Mannr

Vascular Calcification
S. E. Rosas, P. Raggi, M. J. Budoff, and M. Ketteler

Thrombotic Microangiopathies
J. E. Sadler, G. B. Appel, W. F. Clark, and C. Licht

The Changing Face of FSGS/MCD
M. Kretzler, J. Radhakrishnan, D. C. Cattran, and J. B. Kopp

Infectious Risk in Renal Replacement Therapy
N. D. Vaziri, A. J. Collins, N. R. Powe, and C. E. Lok



January 26, 2010

Cohen  

Berns  
Primary Care for Nephrologists: HIV Nephropathy   
Arthur H. Cohen, MD; and Jeffrey S. Berns, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Cohen: What are the nephropathies directly related to HIV infection? How have they changed in the era of HAART? What happened to the tubuloreticular inclusions? Tubular microcystic dilatation? ATN-like lesions? What about those related to complications of HIV? How does the immune complex-like lesion relate to HIV infection? What is the pathogenesis of the lupus-like lesions in HIV? What characterizes indinavir and tenofovir nephrotoxicities? Dr. Berns: What are the pitfalls of assessing GFR in patients with HIV? Why should cystatin estimates be avoided? What has follow-up data been on efficacy of ACE inhibitors and HIVAN? Under which conditions, if any, might corticosteroid treatment be considered? How does one approach TTP/TMA in HIV-infected patients? Are there any substantial access-related issues in hemodialysis patients with HIV?


Ronco  

Ross  

Berl  
Understanding the Kidney - Heart Connection   
Claudio Ronco, MD, Edward A. Ross, MD, and Tomas Berl, MD
(ASN Renal Week Official Symposium, 2009.)
Ronco: What is the cardiorenal syndrome? How do we define it? What are the different subtypes? How does each impact clinical outcomes? Why is an early diagnosis of AKI important? What is the role of new biomarkers in the diagnosis? Ross: How prevalent is anemia in heart failure and what are its mechanisms? What is the impact of anemia in CHF on hospitalization and survival? What do the trials of correcting anemia show? Why are the results conflicting? What should Hb targets be in view of the TREAT results? What is the RED-HF trial? Berl: What is the prognostic importance of hyponatremia in heart failure patients, and what are the benefits of correcting in it randomized, controlled trials? What is the comparable efficacy of vasopressin antagonists in SIADH and heart failure? What do randomized trials show for use of V2-antagonists in terms of hard outcomes?


Bakris  

Wright  

Molitch  
Controlling Diabetes Mellitus by Targeting the Kidney   
George L. Bakris, MD, Ernest M. Wright, PhD, Mark E. Molitch, MD
(ASN Renal Week Official Symposium, 2009.)
Molitch: What is the natural history of type 2 diabetes and how does this affect our choice of therapeutic regimens? What is the basis of GLP-1 agonists and DPP-IV inhibitors? What should the initial therapeutic intervention be? When is metformin to be used? What drugs should subsequently be added? When is insulin a preferred treatment? What are current concerns with the thiazolidinediones? What potential problems are there with each drug class in CKD? Wright: How do the kidneys handle glucose and what are the main transporters involved? What happens to patients with familial renal glucosuria, a loss-of-function mutation in SGLT-2 in terms risk of hypoglycemia and change in renal function? What drugs have an effect on SGLT-2? Bakris: What effects do SGLT-2 inhibitors have on HbA1c and on body weight? What are the potential adverse events identified in the initial trials?


ASN Renal Week 2009
now in MP3
AUDIOFILE LIST (ASN Renal Week 2009)
(37 talks)
Management of Common Problems in Polycystic Kidney Disease
K. Ty Bae, A. B. Chapman and V. E. Torres

Literature Review: ICU Nephrology and Critical Care Medicine
K. D. Liu, and A. J. Tolwani

Hypertensive Nephrosclerosis: Cause or Consequence of Hypertension
R. D. Toto, B. I. Freedman, J. Lewis, and F. C. Luft

Hepatitis C and Renal Disease
C. L. Berg, R. D. Bloom, R. S. Brown

Are We Making Progress in Vascular Access?
A. S. Yevzlin, A. Asif, D. M. Hentschel, and A. Q. Urbanes

Reducing Health Disparities in CKD
M. H. Chin, P. W. Eggers, W. M. McClellan, and N. R. Powe

Primary Care for Nephrologists: HIV Nephropathy
P. L. Kimmel, A.H. Cohen, J. S. Berns, and S.J. Tomlanovich

Peritoneal Dialysis: A Bright Past and Unknown Future
I. Teitelbaum, F. O. Finkelstein, P. G. Blake, and M. D. Faber

Desperately Seeking a Donor: Difficult Choices in Kidney Donation
F. L. Delmonico, A. B. Leichtman, J. A. Fishman, and D. L. Segev

Cardiorenal Syndrome
C. Ronco, A. S. Maisel, and A. A. House



January 4, 2010

Flores-
Suarez
 

Segelmark  

Specks  
Therapeutic Issues in Crescentic Glomerulonephritis and Vasculitis   
Luis F. Flores-Suarez, MD, PhD, Marten Segelmark, MD, and Ulrich Specks, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2008.)
Flores-Suarez: How can we subgroup the vasculitides based on presentation? What are the complications associated with cyclophosphamide? For early, generalized disease, what did NORAM show re methotrexate? The Cleveland Clinic study? What did CYCLOPS show regarding IV cyclophosphamide? What did MEPEX show regarding use of plasma exchange in severe disease? Does azathioprine or MMF work? What about rituximab? What are the early results of the RITUXVAS study? What are the prognostic factors of ANCA-vasculitis? Biomarkers? Segelmark: How do we approach the patient with vasculitis who has had multiple relapses? What are the different types of therapy resistance? What is standard initial therapy? What are the choices to treat relapses, and what do studies show regarding their efficacy? Specks: How do we approach the pulmonary and other extrarenal manifestations of vasculitis? What are the manifestations of vasculitis in the alveoli, tracheobronchial tree, and nasal cartilages? What is the differential diagnosis and how do we decide if it is vasculitis or not? How do treatment options differ from those in patients with primarily renal disease?


Schrier  

Wadei  

Davenport  
Hepatorenal Syndrome   
Robert W. Schrier, MD, Hani M. Wadei, MD, and Andrew Davenport, MD
(ASN Renal Week Official Symposium, 2009.)
Schrier: What is the pathophysiology of hepatorenal syndrome? What components of the underfilling and systemic arterial vasodilatation hypotheses are important clinically? What is the role of distal sodium delivery? How is hyponatremia important as a marker of outcome in cirrhosis? What happens with aldosterone antagonism? Mannitol plus atrial natriuretic peptide? What is the evidence that nitric oxide is important? Wadei: Management options include vasoconstrictors, TIPS, a combination of these, renal replacement therapy, and transplantation. When is each of these indicated? What vasoconstrictors should one use? What do studies with terlipressin show? Is albumin infusion independently useful? What are the predictors of reversal of hepatorenal syndrome with treatment? Davenport: How do we characterize AKI (acute kidney insufficiency) in patients with liver failure? What are the determinants of recovery? What is the evidence regarding harmful effects of intradialytic hypotension? How can we prevent this using thermal effects, midodrine, and other maneuvers? What to kidney biopsy studies show in patients with AKI and liver failure? How might this guide us in therapy? When should combined liver-kidney transplant be considered?


Salusky  

Gutierrez  

Bushinsky  
New Frontiers in Chronic Kidney Disease-Mineral Bone Disorders   
Isidro B. Salusky, MD; Orlando M. Gutierrez, MD, MMSc; and David A. Bushinsky, MD. (Moderator: Myles S. Wolf, MD)
(ASN Renal Week Official Symposium, 2009.)
Salusky: As CKD progresses, 1,25D goes down very early. Why? What are the 2 ways that FGF23 is involved? What organ makes FGF23, and how is FGF23 involved in maintaining architecture of bone? Gutierrez: How is FGF23 related to outcomes in CKD and in incident dialysis patients? How is FGF23 related to left ventricular hypertrophy? Does FGF23 associated with CKD progression? Bushinsky: How is coronary calcification related to mortality in CKD? How might calcium balance in CKD affect calcification? What should be the goal in terms of net calcium balance in CKD? What are the factors that affect calcium balance in CKD patients, and how are they different from nonuremic healhies? What's the role of the dialysate calcium concentration? How is gastrointestinal absorption of calcium affected by vitamin D? What is the dietary calcium intake associated with a zero calcium balance when dialysate Ca is 2.5 mEq/L, with and without vitamin D?


Himmelfarb  

Hakim  

Moran  

Nissenson  

Saran  

Winkelmayer  
Impact of Bundled Payments on Care for ESRD Patients   
Ray Hakim, MD; John Moran, MD; Allen Nissenson, MD; Rajiv Saran, MD; and Wolfgang Winkelmayer, MD (Moderator: Jonathan Himmelfarb, MD)
(ASN Renal Week Official Symposium, 2009.)
Panel Discussions (1) What is MIPPA, and how did CMS propose to implement it with the proposed bundled reimbursement system? (2) What are the controversial aspects of bundling? (3) How might bundling impact on patient care? (4) How might bundling limit physicians' choices? (5) What does the nephrology community have to learn from bundling? How can we intercede to make sure that bundling is fairly applied? (6) Audience questions.







HDCN home
/about our site / subscribe to key zone / register for free zone
update email address / subscription status / forget your password?